{"id":412752,"date":"2021-01-12T06:48:38","date_gmt":"2021-01-12T11:48:38","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=412752"},"modified":"2021-01-12T06:48:38","modified_gmt":"2021-01-12T11:48:38","slug":"u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/","title":{"rendered":"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older"},"content":{"rendered":"

<\/p>\n

U.S. FDA Accepts for Priority Review the Biologics License Application for V114, <\/b>Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older<\/b><\/p>\n

KENILWORTH, N.J.–(BUSINESS WIRE<\/a>)–
\nMerck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for V114, Merck\u2019s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults 18 years of age and older. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action date, of July 18, 2021. The European Medicines Agency is also reviewing an application for licensure of V114 in adults.\n<\/p>\n

\n\u201cInvasive pneumococcal disease in adults is on the rise in many countries, driven by highly-invasive serotypes including serotype 3, which is included in the currently licensed pneumococcal conjugate vaccine, as well as serotypes not included, such as serotypes 22F and 33F,\u201d said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. \u201cBuilding on our nearly 40 years of experience with PNEUMOVAX\u00ae <\/sup>23, Pneumococcal Vaccine Polyvalent, we have developed V114 as another potentially important option to help protect more adults from invasive pneumococcal disease, especially those who are at increased risk. We look forward to working with the FDA during the review of this application.\u201d\n<\/p>\n

\nThe BLA and priority review designation are supported by results from Phase 2 and Phase 3 clinical studies in a variety of adult populations, including healthy adults and those at increased risk, such as adults with chronic medical conditions, adults with HIV, and those 65 years of age and older. Additional studies in the BLA support the potential use of V114 in various real-world clinical settings, including in co-administration with the quadrivalent influenza vaccine and as part of a sequential administration with PNEUMOVAX 23, and demonstrate equivalent performance among consecutive lots of V114. The FDA grants priority review to medicines and vaccines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment or prevention of a serious condition.\n<\/p>\n

About V114<\/b><\/p>\n

\nV114 is Merck\u2019s investigational 15-valent pneumococcal conjugate vaccine candidate for the prevention of invasive pneumococcal disease in adults. V114 consists of pneumococcal polysaccharides from 15 serotypes conjugated to a CRM197 carrier protein and includes serotypes 22F and 33F, which are commonly associated with invasive pneumococcal disease in older adults worldwide and are not contained in the pneumococcal conjugate vaccine currently licensed for use in adults. Merck is also developing V114 for use in children. An overview of the late-stage development program for V114 is available here<\/a>.\n<\/p>\n

\nV114 previously received Breakthrough Therapy Designation from the FDA for the prevention of invasive pneumococcal disease in pediatric patients 6 weeks to 18 years of age and adults 18 years of age and older.\n<\/p>\n

Indication for PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent)<\/b><\/p>\n

\nPNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F).\n<\/p>\n

\nPNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged \u22652 years who are at increased risk for pneumococcal disease.\n<\/p>\n

\nPNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.\n<\/p>\n

Select Safety Information for PNEUMOVAX 23<\/b><\/p>\n

\nDo not administer PNEUMOVAX 23 to individuals with a history of a hypersensitivity reaction to any component of the vaccine.\n<\/p>\n

\nDefer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.\n<\/p>\n

\nUse caution and appropriate care in administering PNEUMOVAX 23 to individuals with severely compromised cardiovascular and\/or pulmonary function in whom a systemic reaction would pose a significant risk.\n<\/p>\n

\nAvailable human data from clinical trials of PNEUMOVAX 23 in pregnancy have not established the presence or absence of a vaccine-associated risk.\n<\/p>\n

\nSince elderly individuals may not tolerate medical interventions as well as younger individuals, a higher frequency and\/or a greater severity of reactions in some older individuals cannot be ruled out.\n<\/p>\n

\nPersons who are immunocompromised, including persons receiving immunosuppressive therapy, may have a diminished immune response to PNEUMOVAX 23.\n<\/p>\n

\nPNEUMOVAX 23 may not be effective in preventing pneumococcal meningitis in patients who have chronic cerebrospinal fluid (CSF) leakage resulting from congenital lesions, skull fractures or neurosurgical procedures.\n<\/p>\n

\nThe most common adverse reactions, reported in >10% of subjects vaccinated with PNEUMOVAX 23 for the first time in a clinical trial, were: injection-site pain\/soreness\/tenderness, injection-site swelling\/induration, headache, injection-site erythema, asthenia and fatigue, and myalgia.\n<\/p>\n

\nFor subjects aged 65 years or older in a clinical study, systemic adverse reactions which were determined by the investigator to be vaccine-related were higher following revaccination than following initial vaccination.\n<\/p>\n

\nVaccination with PNEUMOVAX 23 may not offer 100% protection from pneumococcal infection.\n<\/p>\n

Merck\u2019s Commitment to Infectious Diseases<\/b><\/p>\n

\nFor more than 100 years, Merck has contributed to the discovery and development of novel medicines and vaccines to combat infectious diseases. In addition to a combined portfolio of vaccines and antibacterial, antiviral and antifungal medicines, Merck has multiple programs that span discovery through late-stage development. To learn more about Merck\u2019s infectious diseases pipeline, visit www.merck.com<\/a>.\n<\/p>\n

About Merck<\/b><\/p>\n

\nFor more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world\u2019s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals \u2013 including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases \u2013 as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com<\/a> and connect with us on Twitter<\/a>, Facebook<\/a>, Instagram<\/a>, YouTube<\/a> and LinkedIn<\/a>.\n<\/p>\n

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA<\/b><\/p>\n

\nThis news release of Merck & Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.\n<\/p>\n

\nRisks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.\n<\/p>\n

\nThe company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company\u2019s 2019 Annual Report on Form 10-K and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (www.sec.gov<\/a>).\n<\/p>\n

Please see Prescribing Information for PNEUMOVAX 23
\n
at http:\/\/www.merck.com\/product\/usa\/pi_circulars\/p\/pneumovax_23\/pneumovax_pi.pdf
\n<\/a>
<\/span>and Patient Information for PNEUMOVAX 23
\n
at http:\/\/www.merck.com\/product\/usa\/pi_circulars\/p\/pneumovax_23\/pneumovax_ppi.pdf<\/a>.<\/b><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210112005398\/en\/<\/a><\/span><\/p>\n

\nMedia:\n<\/p>\n

\nPatrick Ryan
\n
(908) 740-1038
\n
Kim Hamilton
\n
(908) 391-0131\n<\/p>\n

\nInvestors:\n<\/p>\n

\nPeter Dannenbaum
\n
(908) 740-1037
\n
Raychel Kruper
\n
(908) 740-2107\n<\/p>\n

KEYWORDS:<\/b> New Jersey United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology FDA Health General Health Pharmaceutical Oncology Other Science Research Science Veterinary Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for V114, Merck\u2019s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults 18 years of age and older. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action date, of July 18, 2021. The European Medicines Agency is also reviewing an application for licensure of V114 in adults. \u201cInvasive pneumococcal disease … <\/p>\n

Continue reading “U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-412752","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nU.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for V114, Merck\u2019s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults 18 years of age and older. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action date, of July 18, 2021. The European Medicines Agency is also reviewing an application for licensure of V114 in adults. \u201cInvasive pneumococcal disease … Continue reading "U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-12T11:48:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210112005398r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older\",\"datePublished\":\"2021-01-12T11:48:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\\\/\"},\"wordCount\":1428,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210112005398r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\\\/\",\"name\":\"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210112005398r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-01-12T11:48:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210112005398r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210112005398r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/","og_locale":"en_US","og_type":"article","og_title":"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older - Market Newsdesk","og_description":"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for V114, Merck\u2019s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults 18 years of age and older. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action date, of July 18, 2021. The European Medicines Agency is also reviewing an application for licensure of V114 in adults. \u201cInvasive pneumococcal disease … Continue reading \"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-12T11:48:38+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210112005398r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older","datePublished":"2021-01-12T11:48:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/"},"wordCount":1428,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210112005398r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/","name":"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210112005398r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-01-12T11:48:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210112005398r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210112005398r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck\u2019s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412752","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=412752"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412752\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=412752"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=412752"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=412752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}